Circulating Tumour DNA Is a Biomarker of Response in Angioimmunoblastic T-Cell Lymphoma

Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive subtype of non-Hodgkin lymphoma, the monitoring of which is largely restricted to radiological methods. Diagnosis relies on identifying characteristic clinicopathological features, supported by the detection of recurrent somatic mutations in <i>RHOA</i>, <i>TET2</i>, <i>IDH2</i> and <i>DNMT3A</i>. The characteristic molecular profile of AITL and the high levels of circulating tumour DNA (ctDNA) measurable in AITL before treatment makes this an attractive lymphoma subtype in which to further investigate the role of ctDNA monitoring. The detection of somatic mutations in pre-treatment AITL-containing tissue samples was compared to those detected in pre-treatment ctDNA samples in a cohort of 12 patients. Changes in ctDNA somatic mutation burden over time were then correlated with radiological response. All six paired pre-treatment ctDNA and tissue samples had variants in common. All (8/8) previously ctDNA-detectable <i>IDH2</i> and <i>RHOA</i> variants were undetectable in ctDNA samples at the time of end-of-treatment complete metabolic response (CMR). In comparison, the majority of both previously ctDNA-detectable <i>DNMT3A</i> variants (3/4) and <i>TET2</i> variants (6/11) were detectable in ctDNA samples at the time of end-of-treatment CMR. These observations suggest that <i>IDH2</i>/<i>RHOA</i> variants may be more reliable markers of measurable residual disease in AITL than <i>DNMT3A</i>/<i>TET2</i> variants.